U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Contraction as	- for form 4440P/DTO				Complete if Known	(IPE)
Substitute for form 1449B/PTO		Application Number	10/734,731	10,00		
ł	INFORMATION DI	SCLOSUR	E	Filing Date	December 15, 2003	- 31
l	STATEMENT BY			First Named Inventor	Eberhard WEIHE	MM 2 5 2003
			•	Art Unit	1647	WAN -
	(use as many sheets a	s necessary)		Examiner Name	C. J. Nichols	The said
Sheet	1	of	1	Attorney Docket Number	029310.52995US	S TRADEWAS

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
55	AA	P. G. GUNASEKAR, et al., "NMDA Receptor Activation Produces Concurrent Generation of Nitric Oxide and Reactive Oxygen Species: Implication for Cell Death", Journal of Neurochemistry, 1995, pp. 2016-2021, vol. 65, no. 5, Lippincott-Raven Publishers, Philadelphia, International Society for Neurochemistry	
	1		
,		·	
		/	
Examiner Signature	T	Date Considered GOGOS	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 

'Applicant's unique citation designation number (optional). 

'Applicant's unique citation designation number (optional). 

'Applicant's to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

C. J. Nichols

029310.52995US

Complete if Known Substitute for form 1449A/PTO 10/734,731 **Application Number** INFORMATION DISCLOSURE December 15, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor **Eberhard Weihe** 1647 Art Unit

TRADE

Sheet

U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US- 5,262,311	11-16-1993	Arthur B. Pardee et al.			
		US-					

**Examiner Name** 

Attorney Docket Number

(use as many sheets as necessary)

		FOREIC	N PATENT DOC	UMENTS		
Examiner	Cite	Foreign Patent Document  Country Code <sup>3</sup> –Number <sup>4</sup> –Kind Code <sup>3</sup> ( <i>if known</i> )	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	7⁵
Initials'	No.'	WO 96/34288	10-31-1996	Eli Lilly and Company	Figures Appear	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
SS	AC	DAVID BAUER ET AL., "Identification of Differentially Expressed mRNA Species by an Improved Display Technique (DDRT-PCR)", Nucleic Acids Research, 1993, pp. 4272-4280, Vol .21, No. 18, Oxford University Press	
85	AD	CHIH-CHENG CHEN ET AL., "A P2X Purinoceptor Expressed by a Subset of Sensory Neurons", Letters to Nature, October 5, 1995, pp. 428-431, Vol. 377	
22	AE	C.E. FIALLOS-ESTRADA ET AL., "Long-Lasting Increase of Nitric Oxide Synthase Immunoreactivity, NADPH-Diaphorase Reaction and c-JUN Co-Expression in Rat Dorsal Root Ganglion Neurons Following Sciatic Nerve Transection", Neuroscience Letters, 1993, pp. 169-173, 150, Elsevier Scientific Publishers Ireland Ltd.	
SJ	AF	V. HÖLLT ET AL., "Prodynorphin Gene Expression is Enhanced in the Spinal Cord of Chronic Arthritic Rats", Neuroscience Letters, 1987, pp. 90-94, Vol. 73, Elsevier Scientific Publishers Ireland Ltd.	

Examiner Signature	Date Considered	6/06/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/734,731	
	INFORMATION D	ISCLOSII	RF	Filing Date	December 15, 2003	
	STATEMENT BY			First Named Inventor	Eberhard Weihe	
	SIAILMLMIDI	AI I LIVA		Art Unit	1647	
	(use as many sheets	as necessary	)	Examiner Name	C. J. Nichols	
Sheet	2	of	7	Attorney Docket Number	029310.52995US	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
55	AG	JI RU-RONG, "Expression of μ-, δ-, and κ-Opioid Receptor-Like Immunoreactivities in Rat Dorsal Root Ganglia after Carrageenan-Induced Inflammation", The Journal of Neuroscience, December 1995, pp. 8156-8166, Vol. 15, No. 12, 1995, Society for Neuroscience					
12	AH	KEIKO MAEKAWA, "Expression of $\mu$ -and $\kappa$ - but not $\delta$ -, Opiod Receptor mRNAs is Enhanced in the Spiral Dorsal Horn of the Arthritic Rats, Pain, 1995, pp. 365-371, Vol. 64, Elsevier Science B.V.					
22	Al	ABDI A. MOHIT ET AL., "p49 <sup>3F12</sup> Kinase: A Novel MAP Kinase Expressed in a Subset of Neurons in the Human Nervous System", Neuron, January 1995, pp. 67-78, Vol. 14, Cell Press					
55	ĀJ	M.A. RUDA ET AL., "In situ Hybridization Histochemistry and Immunocytochemistry Reveal an Increase in Spinal Dynorphin Biosynthesis in a Rat Model of Peripheral Inflammation and Hyperalgesia", Neurobiology, January 1988, pp. 622-626, Vol. 85, Proc. Natl. Acad. Sci., USA					
· <b>ζ</b>	AK	VALERIE M.K. VERGE ET AL., "Marked Increase in Nitric Oxide Synthase mRNA in Rat Dorsal Root Ganglia after Peripheral Axotomy: <i>In situ</i> Hybridization and Functional Studies", Neurobiology, December 1992, pp. 11617-11621, Vol. 89, Proc. Natl. Acad. Sci., USA					
7)	AL	ANDREW F. WILKS, "Two Putative Protein-Tyrosine Kinases Identified by Application of the Polymerase Chain Reaction", Genetics, March 1989, pp. 1603-1607, Vol. 86, Proc. Natl. Acad. Sci., USA					
55	AM	X. ZHANG ET AL., "Marked Increase in Cholecystokinin B Receptor Messenger RNA Levels in Rat Dorsal Root Ganglia After Peripheral Axotomy", Neuroscience, 1993, pp. 227-233, Vol. 57, No. 2, Pergamon Press Ltd., Great Britain					
$\searrow$	AN	ARMEN N. AKOPIAN ET AL., "A Tetrodotoxin –Resistant Voltage-Gated Sodium Channel Expressed by Sensory Neurons", Letters to Nature, January 18, 1996, pp. 257-262, Vol. 379					
Examiner Signature	T	Date Considered XX/A					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known				
Substitute	e for form 1449B/PTO			Application Number	10/734,731			
	INFORMATION DISC	OS	IRE	Filing Date	December 15, 2003			
	STATEMENT BY APP			First Named Inventor	Eberhard Weihe			
ĺ	STATEMENT DI ALI	LIU		Art Unit	1647	-		
Ì	(use as many sheets as ne	cessa	ry)	Examiner Name	C. J. Nichols			
Sheet	3	of	7	Attorney Docket Number	029310.52995US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\$	AO	DOMINIQUE BESSE ET AL., "Monoarthritis Induces Complex Changes in $\mu$ -, $\delta$ -, and $\kappa$ -Opioid Binding Sites in the Superficial Dorsal Horn of the Rat Spinal Cord", European Journal of Pharmacology, 1992, pp. 123-131, Vol. 223, Elsevier Science Publishers B.V.	
<b>S</b> S	AP	TERENCE J. CODERRE ET AL., "Contribution of Central Neuroplasticity to Pathological Pain: Review of Clinical and Experimental Evidence", Pain, 1993, pp. 259-285, 52, Elsevier Science Publishers B.V.	
- 1	AQ	DAVID DUBUISSON ET AL., "The Formalin Test: A Quantitative of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats", Pain, 1977, pp. 161-174, Vol. 4, Elsevier/North-Holland Biomedical Press	
55.	AR	TATSUO FURUKAWA ET AL., "Identification of New Genes Expressed in a Human Erythroleukemia Cell Line", Blood Cells, Molecules and Diseases, 1996, pp. 11-22, Vol. 22, No. 2, Blood Cells Foundation. LaJolla, California, USA	
.55	AS	BRIAN E. HAWES ET AL., "Nociceptin (ORL-1) and μ-Opioid Receptors Mediate Mitogen-Activated Protein Kinase Activation in CHO Cells Through a G <sub>i</sub> – Coupled Signaling Pathway: Evidence for Distinct Mechanisms of Agonist-Mediated Desensitization", Journal of Neurochemistry, 1998, pp. 1024-1033, Vol. 71, No. 3, Lippincott-Raven Publishers, Philadelphia, PA, USA	
22	AT	M. HUBANK ET AL., "Identifying Differences in mRNA Expression by Representational Difference Analysis of cDNA", Nucleic Acids Research, 1994, pp. 5640-5648, Vol. 22, No. 25	
55\$	AU	SVEN KLUSSMANN ET AL., "Mirror-Image RNA that Binds D-Adenosine", Nature Biotechnology, September 1996, pp. 1112-1115, Vol. 14	
SS	AV	LING-YUAN LI ET AL., "The Stimulatory Effect of Opiods on Mitogen-Activated Proteins Kinase in Chinese Hamster Ovary Cells Transfected to Express $\mu$ -Opioid Receptors", Molecular Pharmacology, pp. 599-602, Vol. 50, The American Society of Pharmacology and Experimental Therapeutics	
Examiner Signature		Date Considered 6/80/85	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete If Known			
Substitute	for form 1449B/PTO			Application Number	10/734,731		
	INFORMATION DIS	SCI OSI	IRE	Filing Date	December 15, 2003		
	STATEMENT BY			First Named Inventor	Eberhard Weihe		
	SIAILMENT DI A		****	Art Unit	1647		
	(use as many sheets a	s necessa:	ny)	Examiner Name	C. J. Nichols		
Sheet	4	of	7	Attorney Docket Number	029310.52995US		

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2				
55	AW	AXEL METHNER ET AL., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed During Bone Development", Biochemical and Biophysical Research Communications, 1997, pp. 336-342, Vol. 233, No. 2, Article No. RC976455, Academic Press					
SS	AX	K. NOGUCHI ET AL., "Gene Regulation in an Ascending Nociceptive Pathway: Inflammation-Induced Increase in Preprotachykinin mRNA in Rat Lamina I Spinal Projection Neurons", The Journal of Neuroscience, July 1992, pp. 2563-2572, Vol. 12, No. 7, Society for Neuroscience					
25	AY	A. SOLODKIN ET AL., "Unilateral Hindpaw Inflammation Produces a Bilateral Increase in Nadph-Diaphorase Histochemical Staining in the Rat Lumbar Spinal Cord", Neuroscience, 1992, pp. 495-499, Vol. 51, No. 3, Pergamon Press Ltd., Great Britain					
53.	AZ	JACKSON S. WAN ET AL., "Cloning Differentially Expressed mRNA's", Nature Biotechnology, December 1996, pp. 1685-1691, Vol. 14					
. \$\$	BA	M. ZIMMERMANN ET AL., "Plasticity of the Nervous System at the Systemic, Cellular and Molecular Levels: a Mechanism of Chronic Pain and Hyperalgesia", Progress in Brain Research, 1998, pp. 233-259, Vol. 110, Chapter 18, Elsevier Science B.V.					
2>	ВВ	HIROSHI BABA ET AL., "Peripheral Inflammation Facilitates Aß Fiber-Mediated Synaptic Input to the Substantia Gelatinosa of the Adult Rat Spinal Cord", The Journal of Neuroscience, January 15, 1999, pp. 859-867, Vol. 19., No. 2, Society for					
2)	ВС	JAMES A. BONINI ET AL., "Molecular Cloning and Tissue Expression of a Novel Orphan G Protein Coupled Receptor from Rat Lung", Biochemical and Biophysical Research Communications, 1997, pp. 190-193, Vol. 234, No. 1, Article No. RC976591, Academic Press					
Examiner Signature		Date Considered Considered					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known		
Substitute for form 1449B/PTO					Application Number	10/734,731	
					Filing Date	December 15, 2003	
IN	FORMATION DISCL	.osi	JRE		First Named Inventor	Eberhard Weihe	
S	TATEMENT BY APP	LIC	ANT		Art Unit	1647	
					Examiner Name	C. J. Nichols	
	(use as many sheets as ne	CBSSA	<u>ry)</u>			029310.52995US	
Sheet	5	of	l	7	Attorney Docket Number	023010.02000	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
25	BD	ANTHONY DICKENSON, "Novel Pharmacological Targets in the Treatment of Pain", Pain Reviews, 1995, pp. 1-12, Vol. 2	
35	BE	F. GILLADRON ET AL., "Long Term Increase in CGRP Levels in Rat Spinal Dorsal Horn Following Skin Ultraviolet Irradiation", 1992, pp. 493-496	L
2)	BF	THOMAS HERDEGEN ET AL., "Expression of Nitric Oxide Synthase and Colocalisation with Jun, Fos and Krox Transcription Factors in Spinal Cord Neurons Following Noxious Stimulation of the Rat Hindpaw", Molecular Brain Research, 1994, pp. 245-258, Vol. 22, Elsevier Science B.V.	
5)	BG	STEPHEN P. HUNT ET AL., "Induction of c-fos- Like Protein in Spinal Cord Neurons Stephen P. Hunt ET AL., "Induction of c-fos- Like Protein in Spinal Cord Neurons 1987, pp. 632-634, Vol. 328	
55	вн	L. KUS ET AL., "N-Methyl-D-Aspartate R1 Messenger RNA and [123]MK-801 Binding Decrease in Rat Spinal Cord After Unilateral Hind Paw Inflammation", Neuroscience, 1995, pp. 159-165, Vol. 68, Elsevier Science Ltd., Great Britain	
SS	BI	PENG LIANG ET AL., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science, August 14, 1992, pp. 967-971, Vol. 257	
55	BJ	G.J. MICHAEL ET AL., "Nerve Growth Factor Treatment Increases Brain-Derived Neurotrophic Factor Selectivity in TrkA-Expressing Dorsal Root Ganglion Cells and in Their Central Terminations Within the Spinal Cord", The Journal of Neuroscience, November 1, 1997, pp. 8476-8490, Vol. 17, No. 21, Society for Neuroscience	
5)	BK	by Differential Display Using Amplified RNA", Nucleic Acids Research, 1997, pp. 914, Vol. 25, No. 4, Oxford University Press	1
31	BL	LAUREN SOMOPAYRAC ET AL., "Overcoming Limitations of the mRNA Differential Display Technique", Nucleic Acids Research, 1995, pp. 4738-4739, Vol. 23, No. 2, Oxford University Press	

Signature \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner

considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

				Complete If Known		
Substitute for form 1449B/PTO				Application Number	10/734,731	
	NFORMATION D	ISCLOSUI	RF	Filing Date	December 15, 2003	
	STATEMENT BY			First Named Inventor	Eberhard Weihe	
	OIVIEWEIAI DI	ALL EIGH	••	Art Unit	1647	
	(use as many sheets	as necessary)	1	Examiner Name	C. J. Nichols	
Sheet	6	of	7	Attorney Docket Number	029310.52995US	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
55	ВМ	VICTOR E. VELCULESCU ET AL., "Serial Analysis of Gene Expression", Science, October 20, 1995, pp. 484-487				
5>	BN	JOSEPH B. WATSON ET AL., "Differential cDNA Screening Strategies to Identify Novel Stage-Specific Proteins in the Developing Mammalian Brain", Dev. Neurosci., 1993, pp. 77-86, Vol. 15				
55	ВО	CLIFFORD J. WOOLF ET AL., "Peripheral Nerve Injury Triggers Central Spouting of Myelinated Afferents", Nature, January 2, 1992, pp. 75-78, Vol. 355				
55	BP	YASUO AlHARA ET AL., "Molecular Cloning of a Novel Brain-Type Na*-Dependent Inorganic Phosphate Cotransporter", Journal of Neurochemistry, 2000, pp. 2622-2625, Vol. 74, No. 6, Lippincott Williams & Wilkins Inc., Philadelphia, PA, USA				
. 55	BQ	P.G. GUNASEKAR ET AL., "NMDA Receptor Activation Produces Concurrent Generation of Nitric Oxide and Reactive Oxygen Species: Implication for Cell Death", Journal of Neurochemistry, 1995, pp. 2016-2021, Vol. 65, No. 5, Lippincott-Raven Publishers, Philadelphia, PA, USA				
. \$\$	BR	JOHN D. LEVINE ET AL., "Intraneuronal Substance P Contributes to the Severity of Experimental Arthritis", Science, November 2, 1984, pp. 547-549	ı			
55	BS	YUN FENG ET AL., "Cloning of a Novel Member of the G Protein-Coupled Receptor Family Related to Peptide Receptors <sup>1</sup> ", Biochemical and Biophysical Research Communications, 1997, pp. 651-654, Vol. 231, No. 3, Article No. RC976161, Academic Press				
5)	BT	OSAMU URAYAMA ET AL., "Coincident Induction of K rev -1/rap 1A, rap 1B and H-ras mRNAs in the Rat Spinal Cord by Noxious Stimulation 1.2", Molecular Brain Research, 1997, pp. 331-334, Vol. 45, Elsevier Science B.V.				
ار	BU	T.R. TÖLLE ET AL., Cellular and Subcellular Distribution of NMDAR1 Splice Variant mRNA in Rat Lumbar Spinal Cord Neurons:, 1982, p. S135				
Examiner	т—	Date				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Signature

Considered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute	e for form 1449B/PTO			Application Number	10/734,731	
	INFORMATION DIS	CLOSE	IRE	Filing Date	December 15, 2003	
	STATEMENT BY A			First Named Inventor	Eberhard Weihe	
	OTATEMENT OT A			Art Unit	1647	
·	(use as many sheets as	necessar	y)	Examiner Name	C. J. Nichols	
Sheet	7	of	7	Attorney Docket Number	029310.52995US	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
2>	BV	THOMAS R. TÖLLE, Chronischer Schmerz, 1997, pp. 307-336				
	,					
Examiner	1	Date ( ) L				
Signature	ل	Considered (O)				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 
Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.